The Non-Insured Health Benefits (NIHB) program establishes exemplary coverage for Dexcom’s real-time continuous glucose monitoring system – bringing game-changing technology to more First Nations and ...
Add Yahoo as a preferred source to see more of our stories on Google. Dexcom recalled an Android app for its G6 continuous glucose monitor because of a problem with the app stopping unexpectedly.
Dexcom CGM use is proven to improve glycemic control 1,2 and can reduce the risk of costly long-term diabetes-related complications compared to fingerstick monitoring. 3 BURNABY, British ...
Advances in CGM technology has been life-altering to those living with diabetes. According to the Diabetes Research Institute Foundation, "34.2 million people, or 10.5% of the US population, have ...
BURNABY, British Columbia--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (CGM), is happy to share that people with type 1 diabetes who are ...
After the latest in a series of successful quarters (with $171.2 million in revenue, up 31 percent year over year), DexCom is queuing up some big product launches. On yesterday’s Q4 earnings call, CEO ...
DexCom, Inc. DXCM, announced that its DexCom G6 continuous glucose monitoring (CGM) system can now connect with the Omnipod 5 Automated Insulin Delivery (AID) system in Germany. The Omnipod 5 AID ...
DexCom Inc. (NASDAQ:DXCM) is one of the best medical technology stocks to invest in. On February 12, DexCom Inc. (NASDAQ:DXCM) shared its Q4 2025 earnings and reported $1.26 billion in quarterly ...
After months of international availability, the Dexcom G7 constant glucose monitor received its FDA clearance to distribute in the US. Ahead of the wide rollout, we got to go hands-on with a demo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results